NCT06382142View on ClinicalTrials.gov

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

406

Participants

Timeline

Start Date

June 21, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Triple-Negative Breast Cancer
Interventions
DRUG

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Eribulin

Administration by intravenous bolus for a cycle of 3 weeks.

DRUG

Vinorelbine

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Gemcitabine

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Capecitabine

Oral administration for a cycle of 3 weeks.

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY